SGLT2 抑制剂的心血管获益评价。
A review of cardiovascular benefits of SGLT2 inhibitors.
机构信息
First Department of Clinical Medicine, Shanxi Medical University, Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Province, China.
Department of Cardiology, The 1st Hospital of Shanxi Medical University, Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Shanxi Province, China.
出版信息
Medicine (Baltimore). 2022 Sep 9;101(36):e30310. doi: 10.1097/MD.0000000000030310.
Abstract
Sodium-glucose cotransporter 2 inhibitor (SGLT2I) is a new type of hypoglycemic drug that targets the kidney. As research continues to advance on this topic, it has been found that SGLT2I has multiple protective effects, such as hypoglycemic, cardio-renal protective, antihypertensive, and lipid-lowering effects. This review discusses the current concepts and possible mechanisms of SGLT2I in the treatment of heart failure, myocardial infarction, hypertension, cardiomyopathy and arrhythmia to provide a reference for clinicians to use drugs more reasonably and scientifically.
摘要
钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2I）是一种针对肾脏的新型降糖药物。随着对该领域研究的不断深入，发现 SGLT2I 具有多种保护作用，如降糖、心肾保护、降压和调脂作用。本文就 SGLT2I 治疗心力衰竭、心肌梗死、高血压、心肌病和心律失常的相关新概念和可能机制进行综述，为临床医生更合理、更科学地使用药物提供参考。
相似文献
1
A review of cardiovascular benefits of SGLT2 inhibitors.SGLT2 抑制剂的心血管获益评价。
Medicine (Baltimore). 2022 Sep 9;101(36):e30310. doi: 10.1097/MD.0000000000030310.
2
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.比较胰高血糖素样肽受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者预防主要不良心血管和肾脏结局的效果。
Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.
3
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.钠-葡萄糖共转运蛋白 2 抑制剂的心脏肾脏作用机制：美国心脏病学会临床心脏病学杂志最新观点述评。
J Am Coll Cardiol. 2020 Feb 4;75(4):422-434. doi: 10.1016/j.jacc.2019.11.031.
4
Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.糖尿病：钠-葡萄糖协同转运蛋白2抑制剂对心血管和肾脏的益处：来自CANVAS研究的见解
Nat Rev Nephrol. 2017 Sep;13(9):517-518. doi: 10.1038/nrneph.2017.113. Epub 2017 Aug 7.
5
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.SGLT2 抑制剂在心血管疾病和肾功能障碍中的保护作用机制。
Curr Top Med Chem. 2019;19(20):1818-1849. doi: 10.2174/1568026619666190828161409.
6
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.新型口服降糖药的心血管作用：DPP-4 和 SGLT-2 抑制剂。
Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588.
7
Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂对2型糖尿病患者预防心血管事件和死亡的降压作用：一项系统评价和荟萃分析
Acta Diabetol. 2023 Dec;60(12):1651-1662. doi: 10.1007/s00592-023-02154-4. Epub 2023 Jul 13.
8
Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?在治疗糖尿病时，我们应该联合使用GLP-1受体激动剂和SGLT2抑制剂吗？
Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5.
9
Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白 2 抑制剂对 2 型糖尿病患者心肾保护的代谢和血液动力学效应。
J Diabetes Investig. 2017 Jul;8(4):416-427. doi: 10.1111/jdi.12644. Epub 2017 May 12.
10
SGLT2 Inhibitors in Type 2 Diabetes Mellitus.钠-葡萄糖协同转运蛋白 2 抑制剂在 2 型糖尿病中的应用。
Heart Fail Clin. 2022 Oct;18(4):551-559. doi: 10.1016/j.hfc.2022.03.009.
引用本文的文献
1
Cardiovascular Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Updated Meta-Analysis.2型糖尿病合并慢性肾脏病患者使用钠-葡萄糖协同转运蛋白2抑制剂治疗的心血管结局：一项系统评价和更新的荟萃分析
Korean Circ J. 2024 Sep;54(9):549-561. doi: 10.4070/kcj.2023.0241. Epub 2024 Apr 26.
2
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes.2型糖尿病患者的全面心血管和肾脏保护
J Clin Med. 2023 Jun 8;12(12):3925. doi: 10.3390/jcm12123925.
本文引用的文献
1
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
2
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
3
Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.钠-葡萄糖共转运蛋白 2 抑制剂与心源性猝死或室性心律失常风险的关系：随机对照试验的荟萃分析。
Europace. 2022 Jan 4;24(1):20-30. doi: 10.1093/europace/euab177.
4
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.达格列净治疗射血分数保留和轻度降低的心衰：DELIVER 试验的原理和设计。
Eur J Heart Fail. 2021 Jul;23(7):1217-1225. doi: 10.1002/ejhf.2249. Epub 2021 Jun 9.
5
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）与心律失常：系统评价和荟萃分析。
Cardiovasc Diabetol. 2021 May 7;20(1):100. doi: 10.1186/s12933-021-01293-8.
6
Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.钠-葡萄糖共转运蛋白 2 抑制剂对心房颤动和房扑的保护作用：随机安慰剂对照试验的系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2021 Mar 19;12:619586. doi: 10.3389/fendo.2021.619586. eCollection 2021.
7
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.索格列净治疗伴有近期恶化心力衰竭的糖尿病患者。
N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16.
8
Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial.达格列净可降低 2 型糖尿病患者的动态中心血压和脉搏波速度：一项随机、双盲、安慰剂对照的临床试验。
J Hypertens. 2021 Apr 1;39(4):749-758. doi: 10.1097/HJH.0000000000002690.
9
Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.钠-葡萄糖协同转运蛋白 2 抑制剂与心血管和肾脏结局试验中的心房颤动。
Diabetes Obes Metab. 2021 Jan;23(1):276-280. doi: 10.1111/dom.14211. Epub 2020 Oct 19.
10
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.恩格列净对比安慰剂对 2 型糖尿病急性心肌梗死患者心脏自主神经活性的影响：EMBODY 试验。
Cardiovasc Diabetol. 2020 Sep 25;19(1):148. doi: 10.1186/s12933-020-01127-z.
Zotero 插件